Compugen to Present at Jefferies 2013 Global Healthcare Conference
TEL AVIV--(BUSINESS WIRE)-- Compugen Ltd. (NASDAQ: CGEN) today announced that its Chairman of the Board, Martin S. Gerstel, will be presenting at the Jefferies 2013 Global Healthcare Conference, on Monday, June 3 at 12:30 PM ET, at the Grand Hyatt in New York.
Compugen is a leading drug discovery company focused on therapeutic proteins and monoclonal antibodies to address important unmet needs in the fields of immunology and oncology. The Company utilizes a broad and continuously growing integrated infrastructure of proprietary scientific understandings and predictive platforms, algorithms, machine learning systems and other computational biology capabilities for the in silico (by computer) prediction and selection of product candidates, which are then advanced in its Pipeline Program. The Company's business model includes collaborations covering the further development and commercialization of selected product candidates from its Pipeline Program and various forms of research and discovery agreements, in both cases providing Compugen with potential milestone payments and royalties on product sales or other forms of revenue sharing. In 2012, Compugen established operations in California for the development of oncology and immunology monoclonal antibody therapeutic candidates against Compugen drug targets. For additional information, please visit Compugen's corporate website at www.cgen.com.
Tsipi Haitovsky, +972-52-598-9892
Global Media Liaison
KEYWORDS: United States North America New York Middle East Israel
The article Compugen to Present at Jefferies 2013 Global Healthcare Conference originally appeared on Fool.com.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.